Damora Therapeutics, Inc. Ordinary Shares
DMRA
9 hedge funds and large institutions have $451K invested in Damora Therapeutics, Inc. Ordinary Shares in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
2% more capital invested
Capital invested by funds: $442K → $451K (+$9.12K)
0.77% less ownership
Funds ownership: 10.81% → 10.04% (-0.77%)
18% less funds holding
Funds holding: 11 → 9 (-2)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.52K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$40.3K |
| 2 |
Renaissance Technologies
New York
|
-$2.37K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.9K |
| 4 |
BlackRock
New York
|
-$1.15K |
| 5 |
Barclays
London,
United Kingdom
|
-$98 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NHAS
1
Novo Holdings A/S
Hellerup,
Denmark
| $341K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $49.6K | -$2.37K | -800 | -5% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $45.2K | +$8.52K | +2,880 | +27% |
|
|
4
UBS Group
Zurich,
Switzerland
| $7.89K | +$6K | +2,028 | +712% |
|
|
5
Bank of America
Charlotte,
North Carolina
| $4.19K | +$6 | +2 | +0.2% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $3.21K | -$1.9K | -641 | -40% |
|
|
7
BlackRock
New York
| $341 | -$1.15K | -390 | -80% |
|
|
8
Barclays
London,
United Kingdom
| $341 | -$98 | -33 | -25% |
|
|
SS
9
SBI Securities
Tokyo,
Japan
| $61 | – | – | – |
|
|
10
Squarepoint
New York
| – | -$40.3K | -12,984 | Closed |
|
11
Group One Trading
Chicago,
Illinois
| – | -$9 | -3 | Closed |
|
DMRA Hedge Fund Activity: Q2 2025 in Review
9 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q2 2025, worth a combined $451K — up 2.1% from $442K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of DMRA and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, adding an estimated $8.52K. The largest seller was Squarepoint, exiting entirely with an estimated $40.3K sold.
- 9 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q2 2025, down from 11 in Q1 2025.
- Funds reported $451K of Damora Therapeutics, Inc. Ordinary Shares stock for Q2 2025, up 2.1% quarter-over-quarter.
- 0 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q2 2025 and 2 closed out, a net change of -2 holders.
- The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q2 2025 was Susquehanna International Group, an estimated $8.52K added.
- The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q2 2025 was Squarepoint, an estimated $40.3K sold.
Based on aggregated 13F filings for Q2 2025.